tirzepatide hearing loss Risk of peripheral vestibular disorders and impairment among users of glucagon-like peptide-1 receptor agonists Tepezza Lawsuit | Tepezza Hearing

Between-study heterogeneity was moderate (Q = 11.61, p = 0.170

In the meantime, the FDA has asked the manufacturers of GLP-1s currently on the market to create registries for collecting data on people who get pregnant while using them

Muscle loss

However, the better medication for an individual depends on more than average weight loss

The rationale is straightforward: tirzepatide activates GIP receptors that liraglutide does not touch, so your body needs time to adjust to the new mechanism

Given that the incidence of Ozempic face is low, it may not be a significant concern for most patients considering or already using Ozempic